Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival

Expert Opinion on Drug Safety

Volumn 8, Issue 5, 2009, Pages 507-514

  Saif, Muhammad Wasif ^a   Hashmi, Sharukh ^a   Bell, Diana ^b   Diasio, Robert B ^c  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Capecitabine; Dihydropyrimidine dehydrogenase; Fluorouracil; Pancreatic cancer; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDINE PHOSPHORYLASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR XENOGRAFT;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BIOPSY, FINE-NEEDLE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PRODRUGS; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 69449096563     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903173217     Document Type: Article

References (27)

1. Siegel R, Ward E, Murray T, etal. Cancer statistics, 2007. Jemal A Cancer J Clin 2007;57(1):43-66
2. van den Bosch RP, van Eijck CH, Mulder PG, Jeekel J. Serum CA 19-9 determination in the management of pancreatic cancer. Hepatogastroenterology 1996;43(9):710-713 (Pubitemid 26190132)
3. Cwik G, Wallner G, Skoczylas T, et al. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006;141(10):968-973 (Pubitemid 44583251)
4. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85(4):350-355 (Pubitemid 20140602)
5. Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP 2007;8(3):279-288
6. Saif MW. Antimetabolites. In: DeVita V, Rosenberg S, editors, Principles of Medical Oncology. 8th edition, 2008
7. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000;45(4):291-297 (Pubitemid 30151522)
8. Ishitsuka H. Capecitabine: preclinical pharmacology studies. Invest New Drugs 2000;18(4):343-354
9. Miyadera K, Sumizawa T, Haraguchi M, et al. Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 1995;55(8):1687-1690
10. Sumizawa T, Furukawa T, Haraguchi M, et al. Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem 1993;114(1):9-14 (Pubitemid 23235624)
11. Ishikawa T, Sekiguchi F, Fukase Y, et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58(4):685-690 (Pubitemid 28099478)
12. Konno S, Takebayashi Y, Aiba M, et al. Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma. Cancer Lett 2001;166(1):103-111 (Pubitemid 32274291)
13. Miyake K, Imura S, Yoshizumi T, et al. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer. Int J Clin Oncol 2007;12(2):111-119 (Pubitemid 46632459)
14. Saif MW, Eloubeidi MA, Russo S, et al. PhaseI study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005;23:8679-8687 (Pubitemid 46211511)
15. Saif MW, Black G, Roy S, etal. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer J 2007;13(4):247-256
16. Blanquicett C, Gillespie GY, Nabors LB, et al. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther 2000;1:1139-1145
17. Johnson MR, Wang K, Smith JB, et al. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000;278:175-184 (Pubitemid 30090740)
18. Saif MW, Syrigos K, Mehra R, et al. Dihydropyrimidine dehydrogenase deficiency (dpd) in gi malignancies: experience of 4-years. Pak J Med Sci Q 2007;23(6):832-839
19. Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004;2(8):527-532
20. Saif MW, Seller S, Diasio RB. Atypical toxicity associated with 5-fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? JOP 2008;9(2):226-229
21. Yu XJ, Jiang YJ, Fu DL, Ni QX. The thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio in pancreatic cancer. Zhonghua Zhong Liu Za Zhi 2004;26(10):618-620
22. Jinfeng M, Kimura W, Sakurai F, et al. Prognostic role of angiogenesis and its correlations with thymidine phosphorylase and p53 expression in ductal adenocarcinoma of the pancreas. Hepatogastroenterology 2007;54(78):1635-1640 (Pubitemid 350068442)
23. Nakayama S, Takeda S, Kawase Y, et al. Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer. Ann Surg 2004240(5):840-844
24. Soong R, Shah N, Salto-Tellez M, et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008;19(5):915-919 (Pubitemid 351627307)
25. Terashima M, Fujiwara H, Takagane A, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002;38(18):2375-2381 (Pubitemid 35387489)
26. Fujiwaki R, Hata K, Nakayama K, et al. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol 2000;18(23):3946-3951
27. Hotta T, Taniguchi K, Kobayashi Y, et al. Comparative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in gastric and colorectal cancers. Oncol Rep 2004;11(5):1045-1051